Presbia PLC (LENS) on Focus After Raising In Today’s Session

March 18, 2018 - By Marie Mckinney

Investors sentiment decreased to 0.4 in Q3 2017. Its down 0.85, from 1.25 in 2017Q2. It dived, as 4 investors sold Presbia PLC shares while 1 reduced holdings. 2 funds opened positions while 0 raised stakes. 2.75 million shares or 2.56% less from 2.82 million shares in 2017Q2 were reported.
100,000 were reported by Jefferies Grp Ltd Llc. Royal Bancshares Of Canada reported 2 shares. Fmr Limited Liability Corp owns 2.57M shares for 0% of their portfolio. Vanguard Gp, a Pennsylvania-based fund reported 62,982 shares. State Bank Of America Corp De holds 0% in Presbia PLC (NASDAQ:LENS) or 24 shares. Blackrock holds 0% or 2,007 shares. Geode Cap Mgmt Ltd Company invested in 0% or 14,898 shares.

The stock of Presbia PLC (NASDAQ:LENS) is a huge mover today! The stock increased 11.11% or $0.34 during the last trading session, reaching $3.4. About 78,667 shares traded. Presbia PLC (NASDAQ:LENS) has declined 35.88% since March 18, 2017 and is downtrending. It has underperformed by 52.58% the S&P500.
The move comes after 5 months positive chart setup for the $58.21M company. It was reported on Mar, 18 by We have $3.60 PT which if reached, will make NASDAQ:LENS worth $3.49 million more.

Analysts await Presbia PLC (NASDAQ:LENS) to report earnings on April, 4.

Presbia PLC (NASDAQ:LENS) Ratings Coverage

Among 3 analysts covering Presbia (NASDAQ:LENS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Presbia had 3 analyst reports since May 10, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, May 10 by Rodman & Renshaw. The company was maintained on Wednesday, December 20 by H.C. Wainwright. The stock of Presbia PLC (NASDAQ:LENS) earned “Buy” rating by Jefferies on Thursday, October 5.

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company has market cap of $58.21 million. The firm provides the refractive lens for patient surgeries, as well as accessories for procedures. It currently has negative earnings. It primarily operates in South Korea, Australia, the Netherlands, Ireland, and Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: